PCM
ALNA

Prelude Capital Management’s Allena Pharmaceuticals ALNA Stock Holding History

Prelude Capital Management’s Portfolio ALNA Stock Details ALNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,100
Closed -$14K – 2142
2018
Q2 		$14K Buy
+1,100
New +$15.9K ﹤0.01% 1435

Other funds holding ALNA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prelude Capital Management's ALNA Position: Q3 2018 in Review

Prelude Capital Management sold out of Allena Pharmaceuticals (ALNA) in Q3 2018, closing a stake of 1,100 shares — an estimated $14K sold.

Prelude Capital Management first reported a position in ALNA in Q2 2018 and held it in 1 quarter. The position peaked at $14K in Q2 2018. 46 funds tracked by Wall St. Rank hold ALNA as of Q3 2018.

  • Prelude Capital Management reported no remaining Allena Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Prelude Capital Management sold 1,100 Allena Pharmaceuticals shares in Q3 2018, an estimated $14K.
  • Prelude Capital Management first reported a position in Allena Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Prelude Capital Management's Allena Pharmaceuticals position peaked at $14K in Q2 2018.
  • 46 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q3 2018.

Based on Prelude Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.